The Viet Nam Competition Authority eyed the nation’s pharmaceutical sector at a recent conference, where the regulator addressed the seeming paradox of a low concentration rate but increasing pharmaceutical companies. Reports say the head of the regulator’s Competition Supervision and Management Department spoke about the troublesome pattern of rising prices in the industry, despite the fact that there are nine times more distributors of pharmaceuticals than there are producers – a figure that implies a low concentration rate, usually associated with high competition and lower prices. Tran Phuong Lan stated that merger and acquisition activity could potentially increase competition by allowing foreign rivals into the market.
Featured News
Apple Opens Early Settlement Discussions With DOJ
Jul 17, 2026 by
CPI
South Korean Steelmaker POSCO Expands Supplier Support Pact With Antitrust Regulator
Jul 16, 2026 by
CPI
FCC’s Carr Criticizes California-Led Bid to Block Paramount-Warner Bros. Discovery Deal
Jul 16, 2026 by
CPI
EU Top Court Upholds Antitrust Powers to Seize Corporate Emails
Jul 16, 2026 by
CPI
Uber Launches $14.8 Billion Bid for Delivery Hero in Landmark Food Delivery Deal
Jul 16, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Agentic AI & Antitrust
Jul 16, 2026 by
CPI
AI Agents and Collusion: The Two Faces of Agentic AI
Jul 16, 2026 by
Giovanna Massarotto
Agentic AI’s Regulatory Conundrum
Jul 16, 2026 by
Anant Raut
Inter-AI-Agent Competition
Jul 16, 2026 by
Stefan Thomas
Navigating the Increasing Regulatory Scrutiny of AI-Pricing Tools: Competition and Other Emerging Risks
Jul 16, 2026 by
Mark Krotoski & Vinny Sidhu